172 material Form 8-K filings that 152 companies we cover made with the SEC in September 2024, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
NCR Voyix completed the sale of its digital banking business to an affiliate of Veritas Capital on September 30, 2024, for $2.45 billion in cash plus up to $100 million in contingent payments. The company used part of the proceeds to repay $1.84 billion of debt and other obligations and terminate its trade receivables facility, and the digital banking results will be reported as discontinued operations. The filing does not report revenue, profit or guidance figures for the remaining business.
Sale price: $2.45 billion in cash, subject to a post-closing adjustment, plus up to $100 million in contingent consideration tied to Veritas' future return on invested capital
Debt reduction: $1.84 billion repaid, including $1,587.5 million of term loan, revolver and senior notes and $251.5 million of trade receivables facility
CFO Brian Webb-Walsh said annualized interest expense on remaining bonds is expected to be approximately $55 million
Digital banking results will be reflected as discontinued operations beginning with the quarter ending September 30, 2024
Cintas reported fiscal 2025 first-quarter results for the quarter ended August 31, 2024, with revenue of $2.50 billion, up 6.8%, and diluted EPS of $1.10, up 18.3% from $0.93. The company raised its full-year fiscal 2025 revenue and diluted EPS guidance, which gives shareholders a higher outlook for the year.
Revenue was $2.50 billion, up 6.8% from $2.34 billion; organic revenue growth was 8.0%.
Net income was $452.0 million, up 17.4%, and diluted EPS was $1.10 compared with $0.93.
Diluted EPS guidance for fiscal 2025 was raised to $4.17 to $4.25 from $4.06 to $4.19.
Revenue guidance was raised to $10.22 billion to $10.32 billion from $10.16 billion to $10.31 billion.
Progress reported fiscal third-quarter 2024 revenue of $179 million, up 2% year over year, and GAAP diluted earnings per share of $0.65, up from $0.42. It raised its fiscal 2024 GAAP revenue guidance but lowered its GAAP diluted EPS guidance, and its board approved suspending the quarterly dividend once the $875 million ShareFile acquisition closes.
Q3 revenue $179 million, up 2% year over year; GAAP diluted EPS $0.65 vs. $0.42; non-GAAP diluted EPS $1.26 vs. $1.08.
Annualized Recurring Revenue of $582 million, relatively flat year over year on a constant currency basis.
FY 2024 GAAP revenue guidance raised to $745 million-$755 million from $725 million-$735 million; GAAP diluted EPS guidance lowered to $1.69-$1.81 from $1.98-$2.10.
Board approved suspending the quarterly dividend as of the closing of the $875 million ShareFile acquisition, with capital redirected to debt repayment, M&A and share repurchases.
Roivant's subsidiary Dermavant agreed on September 17, 2024 to be acquired by Organon for up to about $1.2 billion, including a $175 million payment at closing, a $75 million milestone on FDA approval of VTAMA for atopic dermatitis, and up to $950 million in sales-based milestones, plus tiered royalties. Roivant owns about 87% of Dermavant's shares, so the deal would deliver most of the proceeds to Roivant, though the amount depends on future milestones and the closing is subject to conditions.
Organon agreed to acquire Dermavant for up to about $1.2 billion in aggregate cash consideration, including a $175 million payment at closing
Additional $75 million payable on FDA approval of VTAMA for atopic dermatitis, and up to $950 million in tiered net sales milestones
Roivant owns approximately 87% of Dermavant's common and preference shares; shareholder written consent of at least 75% of voting rights was obtained
Expected to close in the fourth quarter of 2024; either party may terminate if not closed by March 17, 2025
Argan's Board declared a 25% increase in the quarterly cash dividend, from $0.30 to $0.375 per common share, payable October 31, 2024 to holders of record on October 23, 2024. The company also promoted Joshua S. Baugher to Senior Vice President, Chief Financial Officer and Treasurer effective September 16, 2024, succeeding Richard H. Deily, who retired as CFO on September 15, 2024. The higher dividend raises the cash return to shareholders, and the CFO change is a leadership transition at the company's finance function.
Quarterly dividend raised from $0.30 to $0.375 per share, or $1.50 annually, declared September 17, 2024
Dividend payable October 31, 2024 to stockholders of record at close of business October 23, 2024
Joshua S. Baugher, age 44, becomes CFO effective September 16, 2024, with a $250,000 base salary
Employment agreements also filed for CEO David H. Watson ($500,000 base salary) and Charles Collins IV
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.